3Q EARNINGS: Merck pursues growth as sales decline
This article was originally published in Scrip
Executive Summary
Merck & Co's third quarter 2014 sales dipped 4% on a year-over-year basis and at $10.6bn the total was slightly below market consensus of $10.68bn, so the company's stock took a small hit on 27 October as investors focused on Merck's strategy to return to growth, which is led by the recently approved cancer immunotherapy Keytruda (pembrolizumab).
You may also be interested in...
Finance Watch: Pfizer Adds $3.5bn To Cash Stockpile, Reduces Stake In Haleon
Public Company Edition: Pfizer’s stake in Haleon dropped from 32% to 22.6% with a massive sale of shares of the GSK consumer health spinout. Also, Galderma prices its Swiss IPO, Madrigal grosses $600m in a post-approval offering and bluebird secured up to $175m in debt.
Finance Watch: Another Bevy Of VC Mega-Rounds, Including $175m For Capstan
Private Company Edition: Capstan and Engrail raised $175m and $157m, respectively, in series B venture capital rounds in addition to Madrigal’s $400m-plus launch and Clasp’s $150m series A.
Roche/Chugai’s Enspryng Not Good Enough In Phase III Myasthenia Gravis Study
Many companies have late-stage myasthenia gravis programs in Phase III, but argenx and its Vyvgart competitors won a reprieve with the failure of IL-6 inhibitor Enspryng (satralizumab).